MNV
Market News Video
MNV MNV 10 Bargains You Can Buy Cheaper Than Insiders Did
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Radius Health is Now Oversold (RDUS)
Tuesday, September 19, 11:57 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Top Buys by Directors: Braunstein's $1M Bet on EGRX
Wednesday, September 20, 3:03 PM ET, by Market News Video Staff

The directors of a company tend to have a unique inside view into the business, ...

Analysts Forecast 24% Gains Ahead For The Holdings of FTXH
Thursday, September 28, 8:19 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Noteworthy Monday Option Activity: HD, ALRM, HRTX
Monday, October 2, 3:23 PM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

Lannett (LCI) Shares Cross Above 200 DMA
Monday, October 2, 4:14 PM ET, by Market News Video Staff

In trading on Monday, shares of Lannett Co., Inc. (LCI) crossed above their 200 day ...

  More articles:  1 2 next »

Heron Therapeutics (HRTX) Shares Cross Below 200 DMA

By Market News Video Staff, Thursday, December 7, 11:44 AM ET
Play Video: Learn About The 200 DMA


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Thursday, shares of Heron Therapeutics Inc (NASDAQ:HRTX) crossed below their 200 day moving average of $15.24, changing hands as low as $15.20 per share. Heron Therapeutics Inc shares are currently trading off about 0.5% on the day. The chart below shows the one year performance of HRTX shares, versus its 200 day moving average:

Heron Therapeutics Inc 200 Day Moving Average Chart

Looking at the chart above, HRTX's low point in its 52 week range is $12.21 per share, with $18.40 as the 52 week high point that compares with a last trade of $15.30.


Can your brain be trained to become a chart-predicting wizard? Click here to find out

According to the ETF Finder at ETF Channel, HRTX makes up 1.47% of the First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) which is trading higher by about 2.9% on the day Thursday.

See what other ETFs contain HRTX
See what other stocks are held by FTXH


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   According   Average   Click   Crossing   ETFs   FTXH   Finder   HRTX   Heron   Looking   Pharmaceuticals   Start   Stocks   Their   Therapeutics   Thursday   Trust   about   average   below   brain   changing   chart   compares   contain   currently   find   hands   held   here   last   makes   moving   other   point   predicting   range   raquo   share   shares   slideshow   that   trading   versus   week   what   which   with   year   your
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Chart Zero Stock Market Game Stock Market Definitions
MNV

Heron Therapeutics (HRTX) Shares Cross Below 200 DMA | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.